Acrylamide Derivative And Use Thereof In Manufacture Of Medicament

An acrylamide derivative represented by formula (I), pharmaceutically acceptable salts and solvates thereof, as well as a medicament containing said acrylamide derivative or its pharmaceutically acceptable salts as the active ingredient, which can be used to treat disorders associated with tyrosine kinase especially Bcr-Abl, including proliferative disorders such as cancers, and inflammation and the like are provided.

Bicyclic heteroaryl inhibitors of pde4

The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.

IONIC FLUIDS

A method for preparing an ionic compound by mixing at least one compound of formula CA-zHO (1) with at least one hydrogen donor and heating the mixture obtained is provided. The said ionic compound remains in a physical state selected from the group consisting of liquid and semisolid at a temperature below 150° C., preferably below 125° C. 19.-. (canceled)10. A process for preparation of an ionic compound that remains in a physical state selected from the group consisting of liquid and semisolid , at a temperature below 150° C. , preferably below 125° C. , comprising mixing at least one compound of Formula CA.zHO (I) with at least one hydrogen donor and heating the resulting mixture to obtain an ionic compound;wherein, C is independently selected from the group consisting of Na, K, Li, Mg, Ca, Cr, Mn, Fe, Co, Mo, Ni, Cu, Zn, Cd, Sn, Pb, St, Bi, La, Ce, Al, Hg, Cs, Rb, Sr, V, Pd, Zr, Au, Pt, quaternary ammonium, immidazolium, phosphonium, and pyridinium, pyrrolidinium;{'sub': 3', '4', '3', '2', '4, 'A is independently selected from the group consisting of Cl, Br, F, I, NO, SO, CHCOO, HCOO and CO; and'}z is 0 to 20.11. The process as claimed in claim 10 , wherein the hydrogen donor is at least one selected from the group consisting of toluene-4-sulphonic acid monohydrate claim 10 , oxalic acid claim 10 , maleic acid claim 10 , citric acid and methane sulfonic acid.12. The process as claimed in claim 10 , wherein the mixture is heated to up to 150° C.13. A process as claimed in claim 10 , further comprising the method step of dissolving the ionic compound in at least one solvent selected from the group consisting of carboxylic acids claim 10 , amides claim 10 , alcohols claim 10 , amines claim 10 , ketones (aldehydes) claim 10 , esters claim 10 , alkyl halides claim 10 , ethers claim 10 , aromatics for example; methanol claim 10 , ethanol claim 10 , propan-1-ol claim 10 , propan-2-ol claim 10 , 1-butanol claim 10 , isobutanol claim 10 , 2-butanol claim 10 , tert- ...

PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY

Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed. 3. The composition of claim 2 , wherein the composition is adapted for administration to a subject.4. The composition of claim 3 , wherein the composition comprises a unit dosage form of compound (3).5. The composition of claim 4 , wherein the unit dosage form delivers to the subject an amount of compound (3) between about 0.01 and about 8 mg/kg.6. The composition of claim 5 , wherein the unit dosage form delivers to the subject an amount of compound (3) of about 0.01 mg/kg claim 5 , about 0.05 mg/kg claim 5 , about 0.10 mg/kg claim 5 , about 0.20 mg/kg claim 5 , about 0.3 mg/kg claim 5 , about 0.35 mg/kg claim 5 , about 0.40 mg/kg claim 5 , about 0.45 mg/kg claim 5 , about 0.50 mg/kg claim 5 , about 0.55 mg/kg claim 5 , about 0.60 mg/kg claim 5 , about 0.65 mg/kg claim 5 , about 0.70 mg/kg claim 5 , about 0.75 mg/kg claim 5 , about 0.80 mg/kg claim 5 , about 0.90 mg/kg claim 5 , about 1 mg/kg claim 5 , about 2 claim 5 , mg/kg claim 5 , about 4 mg/kg claim 5 , about 6 mg/kg claim 5 , or about 8 mg/kg.7. The composition of claim 2 , wherein the composition is in a single dose form.8. The composition of claim 2 , wherein the composition is in dry form.9. The composition of claim 2 , wherein the composition is lyophilized in a sterile container.10. The composition of claim 2 , wherein the composition is contained within a sterile container.11. The composition of claim 10 , wherein the sterile container comprises a machine detectable identifier.12. The composition of claim 2 , further comprising one or more pharmaceutically acceptable excipients in an oral dosage form.13. The composition of claim 2 , further comprising one or more pharmaceutically acceptable carriers in an injectable dosage form.14. The composition of claim 2 , further ...

SHIP1 MODULATORS AND METHODS RELATED THERETO

Compounds of formula (I): 2. The compound of wherein:C1, C4, C11 and C12 are each independently substituted with two hydrogens;C9 is substituted with one hydrogen;C14 is substituted with one hydrogen;C15 is substituted with two hydrogens;{'sup': 1', '8', '9, 'Ris —R—OR;'}{'sup': 2', '8', '9, 'Ris —R—OR;'}{'sup': 4a', '4b', '7', '3, 'sub': 2', '2', '2', '2', '3', '3, 'Ris hydrogen or alkyl, Ris a direct bond to the carbon to which Ris attached, and Ris —CHNHor —CHN(H)C(O)(CH)CH;'}{'sup': '5', 'Ris alkyl;'}{'sup': '6', 'Ris hydrogen;'}{'sup': '7', 'Ris hydrogen;'}{'sup': '8', 'each Ris independently a direct bond or a straight or branched alkylene chain; and'}{'sup': '9', 'each Ris independently hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl.'}3. The compound of wherein:C1, C4, C11 and C12 are each independently substituted with two hydrogens;C9 is substituted with one hydrogen;C14 is substituted with one hydrogen;C15 is substituted with two hydrogens;{'sup': '1', 'Ris —OH;'}{'sup': '2', 'sub': '2', 'Ris —CH—OH;'}{'sup': 4a', '4b', '7', '3, 'sub': 2', '2', '2', '2', '3', '3, 'Ris hydrogen or methyl, Ris a direct bond to the carbon to which Ris attached, and Ris —CHNHor —CHN(H)C(O)(CH)CH;'}{'sup': '5', 'Ris methyl;'}{'sup': '6', 'Ris hydrogen; and'}{'sup': '7', 'Ris hydrogen.'}4. The compound of selected from:(1S,3S,4R)-4-((3aS,6S,7R,7aS)-7-(aminomethyl)-3,3a-dimethyl-3a,4,5,6,7,7a-hexahydro-1H-inden-6-yl)-3-(hydroxymethyl)-4-methylcyclohexanol; andN-(((3aR,6S,7R,7aS)-6-((1R,2S,4S)-4-hydroxy-2-(hydroxymethyl)-1-methylcyclohexyl)-3a-methyl-3a,4,5,6,7,7a-hexahydro-1H-inden-7-yl)methyl)pentanamide.6. The compound of wherein:C1, C4, C11 and C12 are each independently substituted with two hydrogens;C9 is ...

PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY

Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed. 5. A compound according to claim 1 , wherein Ris COH and Ris H or Ris COH and Ris H.6. A compound according to claim 1 , wherein Ris CORand Ris H or Ris COR claim 1 , and Ris H.7. A compound according to claim 1 , wherein Ris H claim 1 , and Ris H.8. A compound according to claim 1 , wherein Ris C-Caryl claim 1 , or alkylaryl having 1 to 3 separate or fused rings and from 6 to about 18 ring carbon atoms.9. A compound according to claim 1 , wherein Ris C-Caryl.10. A compound according to wherein Ris phenyl.11. A compound according to claim 1 , wherein FG is a fluorescent dye moiety which emits in the near infrared spectrum.12. A compound according to claim 1 , wherein FG comprises carbocyanine claim 1 , indocarbocyanine claim 1 , oxacarbocyanine claim 1 , thiacarbocyanine and merocyanine claim 1 , polymethine claim 1 , coumarine claim 1 , rhodamine claim 1 , xanthene claim 1 , fluorescein claim 1 , boron-dipyrromethane (BODIPY) claim 1 , Cy5 claim 1 , Cy5.5 claim 1 , Cy7 claim 1 , VivoTag-680 claim 1 , VivoTag-S680 claim 1 , VivoTag-S750 claim 1 , AlexaFluor660 claim 1 , AlexaFluor680 claim 1 , AlexaFluor700 claim 1 , AlexaFluor750 claim 1 , AlexaFluor790 claim 1 , Dy677 claim 1 , Dy676 claim 1 , Dy682 claim 1 , Dy752 claim 1 , Dy780 claim 1 , DyLight547 claim 1 , Dylight647 claim 1 , HiLyte Fluor 647 claim 1 , HiLyte Fluor 680 claim 1 , HiLyte Fluor 750 claim 1 , IRDye 800CW claim 1 , IRDye 800RS claim 1 , IRDye 700DX claim 1 , ADS780WS claim 1 , ADS830WS claim 1 , and ADS832WS.15. A method of imaging one or more cells claim 1 , organs or tissues by exposing the cell to or administering to an organism an effective amount of a compound according to claim 1 , where the compound includes a fluorescent dye moiety suitable for imaging.16 ...

CONDUCTING REACTIONS IN LEIDENFROST-LEVITATED DROPLETS

The invention generally relates to conducting reactions in Leidenfrost-levitated droplets. 1. A method for forming and collecting a reaction product , the method comprising conducting a reaction within a Leidenfrost-levitated droplet while maintaining a substantially constant volume of the Leidenfrost-levitated droplet , thereby forming a reaction product within the Leidenfrost-levitated droplet; andcollecting the reaction product in the Leidenfrost-levitated droplet without evaporating the Leidenfrost-levitated droplet.2. The method according to claim 1 , further comprising analyzing the reaction product.3. The method according to claim 2 , wherein analyzing is by a mass spectrometry technique.4. The method according to claim 1 , wherein maintaining the substantially constant volume comprises introducing droplets of pure solvent or the reaction mixture to the Leidenfrost-levitated droplet.5. The method according to claim 4 , wherein a rate at which the droplets of the pure solvent or reaction mixture are introduced to the Leidenfrost-levitated droplet is dependent on an evaporation rate of the Leidenfrost-levitated droplet.6. The method according to claim 1 , wherein the method further comprises conducting multiple reactions in multiple separate Leidenfrost-levitated droplets.7. The method according to claim 6 , wherein the multiple separate Leidenfrost-levitated droplets are merged with each other.8. The method according to claim 6 , wherein the multiple reactions are the same.9. The method according to claim 6 , wherein the multiple reactions are different.10. The method according to claim 1 , wherein the method is conducted without the use of surfactants.11. (canceled)12. A method for forming and collecting a reaction product claim 1 , the method comprising:introducing a first liquid droplet onto a heated surface that is at a temperate that is at or above a Leidenfrost point of the first liquid such that the first liquid droplet levitates on the heated surface, ...

AMINATION AND HYDROXYLATION OF ARYLMETAL COMPOUNDS

In one aspect, the present disclosure provides methods of preparing a primary or secondary amine and hydroxylated aromatic compounds. In some embodiments, the aromatic compound may be unsubstituted, substituted, or contain one or more heteroatoms within the rings of the aromatic compound. The methods described herein may be carried out without the need for transition metal catalysts or harsh reaction conditions. 1. A method of preparing an aminoaromatic group or a hydroxyaromatic group comprising:(A) admixing a metal aromatic compound with an oxaziridine compound to form a first reaction mixture under conditions sufficient to cause a reaction to obtain an anionic intermediate;(B) admixing a weak acid with the anionic intermediate and the first reaction mixture to obtain a second reaction mixture under conditions sufficient to obtain an aminoaromatic group or a hydroxyaromatic group.2. The method of claim 1 , wherein the metal of the metal aromatic compound is attached to one of the carbon atoms of the aromatic ring.3. The method of claim 1 , wherein the metal of the metal aromatic compound is a magnesium halide or lithium.48-. (canceled)9. The method of claim 1 , wherein the metal aromatic compound is substituted.10. (canceled)11. The method of claim 9 , wherein the metal aromatic compound is substituted with a substituent wherein the substituent is amino claim 9 , aminosulfonyl claim 9 , carboxy claim 9 , cyano claim 9 , halo claim 9 , hydroxy claim 9 , hydroxyamino claim 9 , hydroxysulfonyl claim 9 , mercapto claim 9 , nitro claim 9 , oxo claim 9 , or thio; or acyl claim 9 , alkoxy claim 9 , cycloalkoxy claim 9 , alkenyloxy claim 9 , aryloxy claim 9 , aralkoxy claim 9 , acyloxy claim 9 , cycloalkylalkoxy claim 9 , heterocycloalkylalkoxy claim 9 , heterocycloalkoxy claim 9 , alkylthio claim 9 , cycloalkylthio claim 9 , amido claim 9 , alkylamino claim 9 , dialkylamino claim 9 , alkylsulfonyl claim 9 , arylsulfonyl claim 9 , or a substituted version of these groups ...

ANTIMICROBIAL AMPHIPHILES AND METHODS FOR THEIR USE

The present invention is directed to compositions useful for antimicrobial applications. These compositions comprise amphiphilic compounds. 2. The pharmaceutical composition of claim 1 , wherein m is 1; n is 0; p is 0; and t is 1.3. The pharmaceutical composition of claim 2 , wherein each of R claim 2 , R claim 2 , and Ris independently Calkyl.4. The pharmaceutical composition of claim 2 , wherein each of R claim 2 , R claim 2 , and Ris methyl.6. The pharmaceutical composition of claim 1 , wherein m is 1; n is 1; p is 0; and t is 1.8. The pharmaceutical composition of claim 6 , wherein each of R claim 6 , R claim 6 , R claim 6 , R claim 6 , R claim 6 , and Rare independently Calkyl.9. The pharmaceutical composition of claim 6 , wherein each of R claim 6 , R claim 6 , R claim 6 , R claim 6 , R claim 6 , and Ris methyl.10. The pharmaceutical composition of claim 6 , wherein R claim 6 , R claim 6 , and Rand R claim 6 , R claim 6 , and R claim 6 , together with the nitrogen atom to which they are attached claim 6 , form a pyridinium or substituted pyridinium.11. The pharmaceutical composition of claim 6 , wherein R claim 6 , R claim 6 , and Rand R claim 6 , R claim 6 , and R claim 6 , together with the nitrogen atom to which they are attached claim 6 , form a pyridinium.13. The pharmaceutical composition of claim 6 , wherein R claim 6 , R claim 6 , and Rand R claim 6 , R claim 6 , and R claim 6 , together with the nitrogen atom to which they are attached claim 6 , form a pyridyl-substituted pyridinium.14. The pharmaceutical composition of claim 6 , wherein R claim 6 , R claim 6 , and Rare each independently Calkyl and R claim 6 , R claim 6 , and R claim 6 , together with the nitrogen atom to which they are attached claim 6 , form a pyridinium or substituted pyridinium.15. The pharmaceutical composition of claim 1 , wherein Ris —Calkyl.16. The pharmaceutical composition of claim 15 , wherein Ris —CH.17. The pharmaceutical composition of claim 15 , wherein Ris —CH.18. The ...

Quinoline Compounds

The present invention relates to compounds I 115-. (canceled)17. The compound of claim 16 , wherein m is 0.18. The compound of claim 16 , wherein n is 0.19. The compound of claim 16 , wherein Rand Rare independently selected from C-C-alkyl.20. The compound of claim 16 , wherein Rand Rindependently are selected from the group consisting of hydrogen claim 16 , F claim 16 , Cl claim 16 , Br and C-C-alkyl claim 16 , or Rand Rtogether with the carbon atom to which they are bound form a saturated three- claim 16 , four- claim 16 , five- or six-membered unsubstituted or substituted carbocycle as defined in .21. The compound of claim 16 , wherein o is 0.22. The compound of claim 16 , wherein Rand Rtogether with the carbon atoms to which they are bound form a five-membered heteroaryl; wherein the heteroaryl contains one claim 16 , two or three heteroatoms selected from the group consisting of N claim 16 , O and S claim 16 , and wherein the heteroaryl carries zero claim 16 , one claim 16 , two claim 16 , three or four substituents (R).23. The compound of claim 16 , wherein Rand Rtogether with the carbon atoms to which they are bound form a six-membered heteroaryl; wherein the heteroaryl contains one claim 16 , two or three heteroatoms selected from the group consisting of N claim 16 , O and S claim 16 , and wherein the heteroaryl carries zero claim 16 , one claim 16 , two claim 16 , three or four substituents (R).25. The intermediate compound IIA as defined in .26. A composition comprising one compound of formula I claim 16 , as defined in claim 16 , an N-oxide or an agriculturally acceptable salt thereof.27. The composition of claim 26 , comprising additionally a further active substance.28. A method for combating phytopathogenic fungi claim 16 , comprising treating the fungi or the materials claim 16 , plants claim 16 , the soil or seeds to be protected against fungal attack with an effective amount of at least one compound of formula I claim 16 , as defined .29. A seed ...

NOVEL SOFT PDE4 INHIBITORS

The present invention relates to new phosphodiesterase inhibitors, more specifically soft PDE4 inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new soft PDE4 inhibitors compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including inflammatory diseases. 116-. (canceled)21. A pharmaceutical composition comprising a compound as defined in and at least one pharmaceutically acceptable carrier claim 17 , diluent claim 17 , excipient claim 17 , or adjuvant.22. A method for preventing or treating at least one disease or disorder associated with PDE4 activity claim 17 , or a disease or disorder that can be alleviated by treatment with a PDE4 inhibitor claim 17 , comprising:{'claim-ref': {'@idref': 'CLM-00017', 'claim 17'}, 'administering to a subject in need thereof a therapeutic effective amount of a compound as defined in .'}23. The method according to wherein said at least one disease or disorder is selected from the group consisting of immunological disorders claim 22 , fibrotic diseases claim 22 , and inflammatory diseases.24. The method according to wherein said at least one disease or disorder is selected from the group comprising idiopathic pulmonary fibrosis claim 22 , inflammatory eye diseases claim 22 , inflammatory airway diseases claim 22 , skin diseases claim 22 , and intestinal diseases.25. The method according to wherein at least one disease is an inflammatory eye disease.26. The method according to wherein said inflammatory eye disease is selected from dry eye disease or allergic eye disease.27. The method according to wherein ...

Composition, fluorinating reagent, and method for producing fluorinated organic compound

An object of the present invention is to provide a method for producing a fluorinated organic compound with a high yield without using carbon tetrachloride in view of the fact that the production of a fluorinated organic compound with a sufficient yield was impossible for a hitherto-known method that uses a fluorinating agent that contains IF 5 -pyridine-HF alone. Another object of the present invention is to provide a fluorinating reagent that is capable of achieving this object. The present invention provides a composition comprising (1) IF 5 and (2) an aprotic solvent (with the proviso that carbon tetrachloride is excluded), wherein the aprotic solvent is contained in an amount within a range of 50 mass ppm to 20 mass %.

METHOD FOR PRODUCTION OF 3-HYDROXYPROPAN-1-ONE COMPOUND, METHOD FOR PRODUCTION OF 2-PROPEN-1-ONE COMPOUND AND METHOD FOR PRODUCTION OF ISOXAZOLINE COMPOUND

There is provided a novel intermediate for producing pesticides. A method for producing the compound of Formula (3) comprises reacting an aromatic ketone compound of Formula (4) and a substituted acetophenone compound of Formula (5) as starting raw materials in an organic solvent or water in the presence or absence of an additive in the presence of a base in a suspended state. A method may comprise dehydrating the compound of Formula (3). A method for producing compound (2) in one step comprises reacting compound (4) and compound (5) to obtain compound (3). Further, a method for producing an isoxazoline compound of Formula (1) comprises reacting compound (2) and a hydroxylamine in an aliphatic or an aromatic hydrocarbon solvent which is optionally substituted by a halogen atom by adding an additive selected from a phase-transfer catalyst, a C-Calcohol and an aprotic polar solvent in the presence of a base and water. 2. The method according to claim 1 , wherein the solvent is an organic solvent and the reaction is conducted in the absence of the additive.3. The method according to claim 1 , wherein the solvent is water and the reaction is conducted in the presence of a water-soluble organic solvent as the additive.4. The method according to claim 1 , wherein the solvent is water and the reaction is conducted in the presence of a surfactant as the additive. This is a Division of application Ser. No. 12/452,347 filed Dec. 28, 2009, which in turn is a National Phase application of PCT/JP2008/061771 filed on Jun. 27, 2008. The disclosures of the prior applications are hereby incorporated by reference herein in their entirety.The present invention relates to a method for producing a 3-hydroxypropan-1-one compound, a 2-propen-1-one compound and an isoxazoline compound which are useful for functional materials such as medical drugs, agricultural chemicals or electronic materials or production intermediates thereof.Methods for producing an isoxazoline compound from a 1,3-bis ...

PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY

Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed. 3. The composition of claim 2 , wherein the composition is adapted for administration to a subject.4. The composition of claim 3 , wherein the composition comprises a unit dosage form of compound (3).5. The composition of claim 4 , wherein the unit dosage form delivers to the subject an amount of compound (3) between about 0.01 and about 8 mg/kg.6. The composition of claim 5 , wherein the unit dosage form delivers to the subject an amount of compound (3) of about 0.01 mg/kg claim 5 , about 0.05 mg/kg claim 5 , about 0.10 mg/kg claim 5 , about 0.20 mg/kg claim 5 , about 0.3 mg/kg claim 5 , about 0.35 mg/kg claim 5 , about 0.40 mg/kg claim 5 , about 0.45 mg/kg claim 5 , about 0.50 mg/kg claim 5 , about 0.55 mg/kg claim 5 , about 0.60 mg/kg claim 5 , about 0.65 mg/kg claim 5 , about 0.70 mg/kg claim 5 , about 0.75 mg/kg claim 5 , about 0.80 mg/kg claim 5 , about 0.90 mg/kg claim 5 , about 1 mg/kg claim 5 , about 2 claim 5 , mg/kg claim 5 , about 4 mg/kg claim 5 , about 6 mg/kg claim 5 , or about 8 mg/kg.7. The composition of claim 2 , wherein the composition is in a single dose form.8. The composition of claim 2 , wherein the composition is in dry form.9. The composition of claim 2 , wherein the composition is lyophilized in a sterile container.10. The composition of claim 2 , wherein the composition is contained within a sterile container.11. The composition of claim 10 , wherein the sterile container comprises a machine detectable identifier.12. The composition of claim 2 , further comprising one or more pharmaceutically acceptable excipients in an oral dosage form.13. The composition of claim 2 , further comprising one or more pharmaceutically acceptable carriers in an injectable dosage form.14. The composition of claim 2 , further ...

Charged ion channel blockers and methods for use

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof:The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, cough, itch, and neurogenic inflammation.

INHIBITORS OF TRPC6

The invention relates to compounds of formula (I) 112-. (canceled)14. The method of claim 13 , wherein the compound is selected from the group consisting of:[4-(6-Amino-pyridazin-3-yl)-piperidin-1-yl]-[5-(4-isopropoxy-phenoxy)-4-methoxy-pyridin-2-yl]-methanone;[4-(6-Amino-pyridazin-3-yl)-piperidin-1-yl]-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone;[4-(6-Amino-pyridazin-3-yl)-piperidin-1-yl]-[5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl]-methanone;[4-(6-Amino-pyridazin-3-yl)-piperidin-1-yl]-[4-methoxy-5-(4-trifluoromethyl-phenoxy)-pyridin-2-yl]-methanone;[4-(6-Amino-pyridazin-3-yl)-piperidin-1-yl]-[5-(4-chloro-phenoxy)-4-methoxy-pyridin-2-yl]-methanone;[4-(6-Amino-pyridazin-3-yl)-piperidin-1-yl]-[5-(4-cyclopropoxy-phenoxy)-4-methoxy-pyridin-2-yl]-methanone;[4-(6-Amino-pyridazin-3-yl)-piperidin-1-yl]-[5-(4-fluoro-benzyloxy)-4-methoxy-pyridin-2-yl]-methanone;[4-(6-Amino-pyridazin-3-yl)-piperidin-1-yl]-[4-methoxy-5-(4-methoxy-phenoxy)-pyridin-2-yl]-methanone;[4-(6-Amino-pyridazin-3-yl)-piperidin-1-yl]-[5-(4-difluoromethoxy-phenoxy)-4-methoxy-pyridin-2-yl]-methanone;[4-(6-Amino-pyridazin-3-yl)-piperidin-1-yl]-[5-(2-fluoro-benzyloxy)-4-methoxy-pyridin-2-yl]-methanone;[4-(6-Amino-pyridazin-3-yl)-piperidin-1-yl]-[4-methoxy-5-(4-trifluoromethoxy-phenoxy)-pyridin-2-yl]-methanone;[4-(6-Amino-pyridazin-3-yl)-piperidin-1-yl]-[5-(phenoxy)-4-ethoxy-pyridin-2-yl]-methanone; and[4-(6-Amino-pyridazin-3-yl)-piperidin-1-yl]-[5-(4-fluoro-phenoxy)-4-ethoxy-pyridin-2-yl]-methanone;or a pharmaceutically acceptable salt thereof.15. The method of claim 14 , wherein the compound is selected from the group consisting of:[4-(6-Amino-pyridazin-3-yl)-piperidin-1-yl]-[5-(4-isopropoxy-phenoxy)-4-methoxy-pyridin-2-yl]-methanone;[4-(6-Amino-pyridazin-3-yl)-piperidin-1-yl]-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone;[4-(6-Amino-pyridazin-3-yl)-piperidin-1-yl]-[5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl]-methanone;[4-(6-Amino-pyridazin-3-yl)-piperidin-1-yl]-[4-methoxy-5-(4-trifluoromethyl-phenoxy)- ...

CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING

The present invention provides contrast agents of the formula [N(A,A,A) M](counter ion(s)) for use in a diagnostic method practiced on the human or animal body. It also refers to the contrast agents, as well as pharmaceutical compositions containing same. Further, it relates to a method of in vitro medical imaging, especially of diagnostic imaging, comprising administering said compound to a sample. 118.-. (canceled)19. A method of diagnostic imaging which comprises administering a patient a contrast agent according .20. The method according to claim 19 , wherein the contrast agent is a magnetic resonance imaging contrast agent.21. The method according to claim 19 , wherein the transition metal is Fe claim 19 , Co claim 19 , Ni claim 19 , and Cu.22. The method according to claim 19 , wherein the contrast agent is water-soluble.23. The method according to claim 19 , wherein A claim 19 , A claim 19 , and Aare the same.24. The method according to claim 19 , wherein the diagnostic method is medical imaging.26. The method according to claim 19 , wherein the counter ion(s) is/are selected from the group consisting of acetate (OAc) claim 19 , chloride (Cl) claim 19 , iodide (I) claim 19 , bromide (Br) claim 19 , nitrate (NO) claim 19 , triflate (OTf) and sulfate (SO).27. The method according to claim 19 , wherein{'sub': 1', '4', '5', '6', '3', '2, 'R, R, R, and Rare independently selected from the group consisting of: H, F, Cl, Br, I methyl, OMe, OH, and CF, wherein Ris H, or OH; and'}{'sub': 3', '3, 'R═H or CH.'}28. The method according to claim 19 , wherein{'sub': 1', '2', '3', '4', '5', '6, 'R, R, R, R, R, and Rare independently selected from the group consisting of{'sub': 3', '1-4', '1-4', '3-7', '3-7', '4-12', '2', '4-12, 'H, OH, SH, CF, CN, halogen, optionally substituted Calkyl, Cheteroalkyl, Ccycloalkyl, Cheterocycloalkyl, Caryl C(O)NHor C(O)OH and Cheteroaryl groups.'}{'sub': 6', '1-4, 'wherein Ris H, OH, or an Calkyl; and'}{'sup': '2', 'sub': 2', '1', '3', '4', ' ...

BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS

Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X is CRor N; Y is CRor N; Z is CRor N; provided that zero or 1 of X, Y, and Z is N; and R, R, R, R, R, R, and Rare define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer. 2. The compound according to or a salt or prodrug thereof claim 1 , wherein:{'sub': '1a', 'claim-text': [{'sub': 3-5', '1-2', '1-2', 'a', 'a', 'a', 'a', '2', '1-2', 'a', '2', '1-2, '(i) hydrogen or Calkyl substituted with 1 to 4 substituents independently selected from F, —CN, —OH, Calkoxy, Cfluoroalkoxy, —NRR, —C(O)NRR, —S(O)(Calkyl), and —NRS(O)(Calkyl);'}, {'sub': y', 'y', '0-3', 'x', 'a', 'a', '1-2', 'x', 'y', '2', '2', 'x, '(ii) —(CRR)R, —(CRR)C(O)R, or —CR(CHCHOH)R; or'}, {'sub': 3-4', '1-2', '1-3', 'a', 'a', 'a', '1-2', 'a', '1-2', '2', '1-2', '2', '1-3', '3-4', '2', '2, '(iii) a cyclic group selected from Ccycloalkyl, azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, and pyridinyl, each substituted with zero or one substituent selected from —OH, —C(O)(Calkyl), —C(O)O(Calkyl), —NRR, —NRC(O)(Calkyl), —NRC(O)O(Calkyl), —S(O)(Calkyl), —S(O)(Cfluoroalkyl), —C(O)(Ccycloalkyl), —C(O)(morpholinyl), —CH(pyridinyl), —S(O)(pyridinyl), morpholinyl, and triazolyl;'}], 'Ris{'sub': '1b', 'claim-text': [{'sub': 1-6', '3', '3-4', 'a', 'a', 'a', 'a', '2', '1-2, '(i) F, —CN, or Calkyl substituted with zero to 3 substituents independently selected from F, —CN, —OH, —CH, Ccycloalkyl, —NRR, —C(O)NRR, and —S(O)(Calkyl); or'}, {'sub': 1-3', '1-3', '1-2', '1-2', '3-6', '1-3', 'y', 'y', '3', '3', '3', '3', '2', '1-3', '2', '1-3, '(ii) azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, pyrrolidinonyl, morpholinyl, pyrrolidinyl, pyridinyl, or pyrimidinyl, each substituted with zero to 4 ...

Remote Heteroaryl Alkenylation With Catalytic Bifunctional Template

We report the design of a catalytic, bifunctional template that binds heterocyclic substrate via reversible coordination instead of covalent linkage, allowing remote site-selective C—H olefination of heterocycles. The two metal centers coordinated to this template play different roles; anchoring substrates to the proximity of catalyst and cleaving the remote C—H bonds respectively. Using this strategy, we demonstrate remote site-selective C—H olefination of heterocyclic substrates which do not have functional group handles for covalently attaching templates. For instance the olefination can be an alkenylation of a 3-phenylpyridine with an acrylate alkyl ester selective for the meta position of the phenyl group with respect to the pyridine, or can be an alkenylation of a quinoline with an acrylate alkyl ester selective for the 5-position of the quinoline. 2. The template compound of wherein X is SO; or L is one of an ethylene or a 1 claim 1 ,1 claim 1 ,2 claim 1 ,2 claim 1 ,-tetramethylethylene linker or a two-carbon moiety comprised by a cyclohexyl ring; or both.3. A method of carrying out an alkenylation of a compound comprising a 3-phenylpyridine group having a hydrogen atom disposed on the phenyl ring meta to the point of attachment to the pyridine ring claim 1 , comprising contacting the compound comprising the 3-phenypyridine group and an acrylate alkyl ester having at least one acrylate 1-hydrogen claim 1 , in the presence of the template compound of formula (I) claim 1 , an N-acylaminoacid claim 1 , a Pd(II) salt claim 1 , an Ag(I) salt claim 1 , and a Cu(II) salt claim 1 , in a solvent milieu comprising 1 claim 1 ,1 claim 1 ,1 claim 1 ,3 claim 1 ,3 claim 1 ,3-hexafluoro-2-propanol (HFIP).4. The method of wherein for the template compound of formua (I) claim 3 , X is SO claim 3 , or L is an ethylene claim 3 , or L is a 1 claim 3 ,1 claim 3 ,2 claim 3 ,2 claim 3 ,-tetramethylethylene linker claim 3 , or any combination thereof.5. The method of claim 3 , ...

PROCESS FOR PREPARING DIHALOPYRIDINES

Processes for manufacturing dihalopyridines without the use of copper salts are described. Additional processes for manufacturing dihalopyridines from niacinamide are described. 2. The process of wherein the iron (III) compound is an iron salt.5. The process of wherein steps (b) and (c) are conducted in the same reaction vessel.6. The process of wherein steps (a) claim 4 , (b) claim 4 , and (c) are conducted in the same reaction vessel.7. The process of wherein the second halogenating agent is selected from the group consisting of group consisting of chlorine claim 4 , N-chlorosuccinimide claim 4 , bromine claim 4 , N-bromosuccinimide claim 4 , hypochlorous acid claim 4 , hypobromous acid claim 4 , alkali metal hypochlorites claim 4 , alkali metal hypobromites claim 4 , and benzyltrimethyl ammonium tribromide.8. The process of wherein the first halogenating agent is selected from the group consisting of bromine claim 3 , N-bromosuccinimide claim 3 , chlorine claim 3 , N-chlorosuccinimide claim 3 , hydrochloric acid and hydrogen peroxide claim 3 , hypochlorous acid claim 3 , hypobromous acid claim 3 , alkali metal hypochlorites claim 3 , alkali metal hypobromites claim 3 , and benzyltrimethyl ammonium tribromide.9. The process of wherein Y is not present.10. The process of wherein Xis chloro.11. The process of wherein Xis chloro.12. The process of wherein Y is absent; and Xand Xare both chloro.13. The process of wherein the iron compound is selected from the group consisting of ferric chloride claim 1 , ferric nitrate claim 1 , ferric sulfate claim 1 , ferrous chloride claim 1 , ferrous nitrate claim 1 , and ferrous sulfate.14. The process of wherein the iron salt is ferric chloride.15. The process of wherein the hydrohalic acid is hydrochloric acid.16. The process of wherein the first halogenating agent is chlorine.17. The process of wherein the second halogenating agent is sodium hypochlorite.18. The process of wherein step (c) conducted at a temperature of about ...

Cyclopropaneamine compound

The present invention provides a compound having a lysine-specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for cancer, and central nervous system diseases, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group or heterocyclic group optionally having substituent(s); R is H, a hydrocarbon group or heterocyclic group optionally having substituent(s); A and R are optionally bonded to each other to form a ring optionally having substituent(s); Q 1 , Q 2 , Q 3 and Q 4 are each a hydrogen atom or a substituent; Q 1 and Q 2 , and Q 3 and Q 4 , are each optionally bonded to each other to form a ring optionally having substituent(s); X is H, an acyclic hydrocarbon group or saturated cyclic group optionally having substituent(s); Y 1 , Y 2 and Y 3 are each H, a hydrocarbon group or heterocyclic group optionally having substituent(s); X and Y 1 , and Y 1 and Y 2 , are each optionally bonded to each other to form a ring optionally having substituent(s); and Z 1 , Z 2 and Z 3 are each H or a substituent, or a salt thereof.

PROTIC-SOLUBLE ORGANIC ELECTROCHROMIC COMPOUNDS

Protic-soluble electrochromic materials, ion-paired electrochromic materials including protic-soluble electrochromic materials, as well as electrochromic media and electrochromic devices incorporating such materials, are provided. The use of protic solvent mixtures, especially mixtures incorporating water, allows for the use of a wider variety of substrate materials. For example, plastics that may be soluble in organic aprotic solvent systems may be used in water-based devices. 2. The electrochromic medium of claim 1 , wherein in Formula (I){'sup': 1', '2', '−', '−', '−', '−, 'sub': 2', 'm', '2', '2', 'n', '2', 'p', '2', 'q', '2, 'Rand Rare each independently —(CH)—CO, —(CH)—P(O)(OH)(O), —(CH)—OP(O)(OH)(O), or —(CH)—S(O)O; and'}m, n, p, and q are each independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.3. The electrochromic medium of claim 1 , wherein in Formula (II){'sup': 12', '21', '−', '−', '−', '−, 'sub': 2', 's', '2', '2', 't', '2', 'u', '2', 'w', '2, 'Rand Rare each independently —(CH)—CO, —(CH)—P(O)(OH)(O), —(CH)—OP(O)(OH)(O), or —(CH)—S(O)O; and'}s, t, u, and w are each independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.4. The electrochromic medium of claim 1 , wherein in Formula (III){'sup': 23', '28', '−', '−', '−', '−, 'sub': 2', 'm′', '2', '2', 'n′', '2', 'p′', '2', 'q′', '2, 'Rand Rare each independently alkyl, —(CH)—CO, —(CH)—P(O)(OH)(O), —(CH)—OP(O)(OH)(O), or —(CH)—S(O)O; and'}m′, n′, p′, and q′ are each independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.8. The electrochromic medium of claim 1 , wherein the protic solvent comprises an alcohol claim 1 , a carboxylic acid claim 1 , a primary amino compound claim 1 , a secondary amino compound claim 1 , water claim 1 , or a mixture of any two or more thereof.9. The electrochromic medium of claim 1 , wherein the protic solvent comprises methanol claim 1 , ethanol claim 1 , isopropanol claim 1 , trifluoroethanol claim 1 , butanol claim 1 , ethylene glycol claim 1 , propylene glycol claim 1 , water claim 1 , or a ...

COMPOUNDS AND METHODS FOR INHIBITING PRODUCTION OF TRIMETHYLAMINE

The invention provides a method of inhibiting the conversion of choline or carnitine to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual a composition comprising a compound set forth in FORMULA (I): 2. The method of claim 1 , wherein the compound is at least one of N-(2-Phenoxyethyl)-2-isothiocyanato-N claim 1 ,N-dimethylethan-1-aminium triflate claim 1 , N-(2-isothiocyanatoethyl)-N claim 1 ,N-dimethylprop-2-yn-1-aminium bromide claim 1 , 3-Isothiocyanato-N claim 1 ,N-diethyl-N-methylpropanaminium iodide claim 1 , and N-(2-isothiocyanatoethyl)-2-(methoxycarbonyl)-N claim 1 ,N-dimethylprop-2-en-1-aminium bromide claim 1 , or pharmaceutically acceptable salts thereof.3. The method of claim 1 , wherein the compound is at least one of N claim 1 ,N-Diethyl-2-isothiocyanato-N-methylpropanaminium iodide claim 1 , N-(2-Bromoethyl)-3-isothiocyanato-N claim 1 ,N-diethylpropan-1-aminium triflate claim 1 , N-(Ethoxypropyl-2 claim 1 ,3-dione)-3-isothiocyanato-N claim 1 ,N-diethylpropan-1-aminium bromide claim 1 , or pharmaceutically acceptable salts thereof.4bacterium. The method of further comprising contacting the with a second agent that is at least one of Omega 3 oil claim 1 , salicylic acid claim 1 , dimethylbutanol claim 1 , garlic oil claim 1 , olive oil claim 1 , hill oil claim 1 , Co enzyme Q-10 claim 1 , a probiotic claim 1 , a prebiotic claim 1 , dietary fiber claim 1 , psyllium husk claim 1 , bismuth salts claim 1 , phytosterols claim 1 , grape seed oil claim 1 , green tea extract claim 1 , vitamin D claim 1 , an antioxidant claim 1 , turmeric claim 1 , curcumin claim 1 , resveratrol claim 1 , activated charcoal claim 1 , or copper chlorophyllin.5. The method of claim 1 , wherein conversion of choline or carnitine to trimethylamine (TMA) is inhibited by from about 1% to about 100%.6. The method of claim 1 , wherein conversion of choline or carnitine to trimethylamine (TMA) is inhibited by at least 50%. ...

Acly inhibitors and uses thereof

The present invention provides compounds useful as inhibitors of ATP citrate lyase (ACLY), compositions thereof, and methods of using the same.

Biaryl derivatives as gpr120 agonists

The present invention relates to biaryl derivatives of Formula 1, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The biaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in the liver or in muscle due to anti-inflammatory action in macrophages, lipocytes, etc., and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, obesity, non-alcoholic fatty liver, steatohepatitis, osteoporosis or inflammation.

Compositions and methods for using fixed biological samples in partition-based assays

The present disclosure provides compositions and methods for using fixed biological samples in partition-based assays. In at least one embodiment, the disclosure provides a composition comprising a fixed biological sample and an un-fixing agent contained in a partition, such as a discrete droplet. In some embodiments, the disclosure provides un-fixing agent compounds capable of catalytically cleaving crosslinks in fixed biological samples, particularly crosslinked nucleic acids, such as RNA.

FUNCTIONALIZED CARBON NANOPARTICLES AND FUNCTIONAL POLYMER FIBERS PREPARED USING THE SAME

The present invention relates to a functionalized carbon nanoparticle prepared by modifying the surface of a carbon nanoparticle with Caryl or heteroaryl substituted with one or more hydroxyl groups, and a functional polymer fiber bound therewith. The functionalized carbon nanoparticles according to the present invention are tightly bound to the polymer fiber, thereby providing the polymer fiber with the properties of carbon nanoparticle. The properties of the carbon nanoparticle being further provided in addition to those of the polymer fiber, the polymer fiber is expected to further expand its scope of application. 1. A functionalized carbon nanoparticle prepared by modifying the surface of a carbon nanoparticle with Caryl or heteroaryl substituted with one or more hydroxyl groups.2. The functionalized carbon nanoparticle according to claim 1 , wherein the carbon nanoparticle includes graphite claim 1 , carbon nanotube claim 1 , or graphene.3. The functionalized carbon nanoparticle according to claim 1 , wherein the Caryl is phenyl.4. The functionalized carbon nanoparticle according to claim 1 , wherein the Caryl or heteroaryl substituted with one or more hydroxyl groups is 2 claim 1 ,4-dihydroxyphenyl; 2-bromophenol; 2 claim 1 ,4 claim 1 ,6-tribromophenol; 2-bromo-4-chlorophenol; 2-bromo-3-methoxyphenol; 2 claim 1 ,4 claim 1 ,6-tribromo-5-methyl-1 claim 1 ,3-benzenediol; 2-bromo-5-methylhydroquinone; 2-bromo-5-nitrophenol; 3 claim 1 ,5-dibromo-2 claim 1 ,4-dihydroxybenzoic acid; 3′-bromo-5′-chloro-2′-hydroxychalcone; 2 claim 1 ,6-dibromophenol; 2 claim 1 ,4-dibromophenol; 1-bromo-2-naphtol; bromohydroquinone; 3-bromo-2-naphtol; 1 claim 1 ,6-dibromo-2-naphtol; 3-bromocatechol; 2 claim 1 ,6-dibromo-1 claim 1 ,5-dihydroxynaphthalene; 2 claim 1 ,5-dibromohydroquinone; 2 claim 1 ,4 claim 1 ,6-tribromoresorcinol; 2 claim 1 ,4-dibromo-1-naphtol; tetrabromohydroquinone; 2-bromo-4-chlorophenol; 2-bromo-p-cresol; 2-bromo-4-fluorophenol; 2-bramo-4-methoxyphenol; 6-bromo-o- ...

Method for preparing pentachloropyridine by utiilizing dctf rectifying short steaming residues

A method for preparing pentachloropyridine by utilizing DCTF rectifying short steaming residues, comprising the following steps: converting polymers in the residues through in situ catalytic cracking and vacuum distillation by using the catalytic degradation function of a catalyst formed by aluminum oxide, silicon oxide, zirconia, 4A zeolite, magnesium oxide, mordenite and HZSM-5 zeolite on the polymers in the DCTF rectifying short steaming residues into small molecular compounds and obtaining pentachloropyridine-containing crude oil; washing the pentachloropyridine-containing crude oil by using an aqueous solution of an alkaline assistant formed by sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, ammonium bicarbonate and sodium hydroxide, carrying out reduced pressure rectification, refrigerating crystallization, vacuum filtration or centrifuging separation, solvent washing, and vacuum drying method sequentially to obtain a pentachloropyridine product with a mass percentage content greater than 95% at a yield being 1-15% of the mass of the DCTF rectifying short steaming residues.

COMPOUND FOR THE TREATMENT OF TUMOURS AND TUMOUR METASTASES

The invention relates to a Smoothened receptor ligand which antagonises the Hedgehog pathway, to pharmaceutical compositions and therapeutic applications thereof, processes for obtaining this compound and novel intermediates useful in these processes. 2. The compound of for use as a medicament.3. The compound of for use in the treatment of cancer claim 1 , wherein said cancer is selected from the list of: non-small cell lung carcinoma; small-cell lung cancer; breast cancer; ovarian tumours; digestive tract tumours; brain cancers; prostate cancer; pancreatic cancer; basal cell carcinoma; Gorlin syndrome; malignant melanoma; squamous cell carcinomas; multiple myeloma; lymphoma; mesenchymal cancers; chronic myeloid leukaemia; endometrial carcinoma; hepatocellular carcinoma.4. The compound of for use in the treatment of brain cancers.5. The compound of for use in the treatment of cancer metastases in the brain.6. The compound of for use in the treatment of a cancer that metastasises to the brain.7. The compound of for use as a Smo receptor antagonist.8. Method of treating cancer with a medicament comprising the compound of claim 1 , said method comprising administering to a patient in need thereof an effective amount of the compound of and treating said patient of said cancer.12. The method of claim 10 , wherein LG is a linear branched or cyclic Calkoxy group.14. Method of preparing the compound of with the compound of as an intermediate or starting material.15. The method of claim 8 , wherein said effective amount ranges from 0.01 to 200 mg/kg. The invention relates to a novel, brain penetrant, Smoothened receptor ligand which antagonises the Hedgehog pathway, to its pharmaceutical applications, to processes for obtaining this compound and to novel intermediates useful in these processes.The inhibition of Hedgehog pathway by Smoothened receptor (Smo) antagonists is now a well known approach to treat a variety of cancer types: compounds known as GDC449, LDE225, IP1926 ...

Method of Producing Epoxy Compound and Catalyst Composition for Epoxidation Reaction

A method of producing an epoxy compound, which comprises reacting hydrogen peroxide with a compound having a carbon-carbon double bond, in the presence of at least one of a tungsten compound and a molybdenum compound; and an onium salt comprising 20 or more carbon atoms and one or more of substituents convertible to a functional group containing an active hydrogen or a salt thereof. 125-. (canceled)27: The onium salt according to claim 26 , which is represented by formula (8) claim 26 , formula (9) claim 26 , or formula (10).28: A catalyst composition claim 26 , comprising:a tungsten compound, a molybdenum compound, or both; and{'claim-ref': {'@idref': 'CLM-00026', 'claim 26'}, 'the onium salt according to .'}29: The catalyst composition according to claim 28 , further comprising a phosphoric acid claim 28 , a phosphonic acid claim 28 , or both claim 28 , which is different from the onium salt.31: The composition according to claim 30 , wherein said epoxy compound α is a compound represented by any one of the following formulae (13) claim 30 , (14) or (15):{'br': None, 'sup': '1', 'sub': 'm1', '(A)-(OG)\u2003\u2003(13)'}{'sup': '1', 'claim-text': {'br': None, 'sub': m2', 'n2', 'm2, 'sup': 21', '2', '22', '2', '21, '(GO)-(A)-[X-(A)]-X-(A)-(OG)\u2003\u2003(14)'}, 'wherein in formula (13), G represents a glycidyl group which is a 2,3-epoxypropanyl group, and said glycidyl group may be substituted with an alkyl group, a phenyl group or an alkoxycarbonyl group; Arepresents an m1-valent aromatic or aliphatic hydrocarbon group that may have a substituent; and m1 represents an integer of 1 or more; provided that a plurality of G contained in one molecule may be same or different;'}{'sup': 21', '22', '21', '22', '2', '22', '2', '21', '22', '2, 'claim-text': {'br': None, 'sup': 3', '3, 'sub': m3', 'n3, 'H-[(A(OG))-X]—H\u2003\u2003(15)'}, 'wherein in formula (14), G represents a glycidyl group, and said glycidyl group may be substituted with an alkyl group, a phenyl group or ...

ELECTROCHROMIC COMPOUNDS WITH IMPROVED COLOR STABILITY IN THEIR RADICAL STATES

The invention relates to an electrochromic device and uses thereof, wherein the electrochromic device includes an electrochromic compound with reduced intermolecular interactions resulting in uncontrolled color changes represented by Formula (I): 2. The electrochromic device of claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , and Rare individually secondary alkyl claim 1 , tertiary alkyl claim 1 , or aryl.3. The electrochromic device of claim 1 , wherein Rand Rare individually aryl.5. The electrochromic device of claim 4 , wherein R claim 4 , R claim 4 , R claim 4 , and Rare individually H or alkyl.6. The electrochromic device of claim 4 , wherein R claim 4 , R claim 4 , R claim 4 , and Rare H claim 4 , and Ris H claim 4 , methyl claim 4 , ethyl claim 4 , propyl claim 4 , iso-propyl claim 4 , butyl claim 4 , sec-butyl claim 4 , or tert-butyl.7. The electrochromic device of claim 4 , wherein Ris alkyl or siloxy alkyl.8. The electrochromic device of claim 4 , wherein Ris H claim 4 , methyl claim 4 , ethyl claim 4 , propyl claim 4 , iso-propyl claim 4 , butyl claim 4 , sec-butyl claim 4 , tert-butyl claim 4 , or —(CH)Si(OR) claim 4 , Ris H or alkyl claim 4 , and n is 1 to 10.9. The electrochromic device of claim 1 , wherein Rand Rare aryl and Rand Rare H.10. The electrochromic device of claim 1 , wherein Rand Rare individually aralkyl claim 1 , C-Calkyl or C-Chydroxyalkyl.12. The electrochromic device of claim 11 , wherein Ris (CH)or 1 claim 11 ,4-phenylene.13. The electrochromic device of claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , and Rare individually H claim 1 , OH claim 1 , or alkyl.14. The electrochromic device of claim 1 , wherein X is F claim 1 , Cl claim 1 , Br claim 1 , I claim 1 , BF claim 1 , PF claim 1 , SbF claim 1 , AsF claim 1 , ClO claim 1 , SOCF claim 1 , N(CN) claim 1 , N(CFSO) claim 1 , C(CFSO) claim 1 , N(SOCF) claim 1 , Al(OC(CF))or BAr claim 1 , wherein Ar is a aryl or fluorinated aryl group.15. The electrochromic device of further ...

PROTIC-SOLUBLE ORGANIC ELECTROCHROMIC COMPOUNDS

Protic-soluble electrochromic materials, ion-paired electrochromic materials including protic-soluble electrochromic materials, as well as electrochromic media and electrochromic devices incorporating such materials, are provided. The use of protic solvent mixtures, especially mixtures incorporating water, allows for the use of a wider variety of substrate materials. For example, plastics that may be soluble in organic aprotic solvent systems may be used in water-based devices. 2. An electrochromic medium comprising{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'an ion-paired electrochromic material of ; and'}a liquid or gel that comprises a protic solvent.3. An electrochromic device comprising:{'claim-ref': {'@idref': 'CLM-00002', 'claim 2'}, 'the electrochromic medium of ; and'}a chamber defined by a first conductive surface of first substrate, a second conductive surface of a second substrate, and a sealing member joining the first substrate to the second substrate,wherein the electrochromic medium is disposed within the chamber.5. An electrochromic medium comprising{'claim-ref': {'@idref': 'CLM-00004', 'claim 4'}, 'an ion-paired electrochromic material of ; and'}a liquid or gel that comprises a protic solvent.6. An electrochromic device comprising:{'claim-ref': {'@idref': 'CLM-00005', 'claim 5'}, 'the electrochromic medium of ; and'}a chamber defined by a first conductive surface of first substrate, a second conductive surface of a second substrate, and a sealing member joining the first substrate to the second substrate,wherein the electrochromic medium is disposed within the chamber. This application is a divisional of U.S. patent application Ser. No. 15/065,808, filed on Mar. 9, 2016, now U.S. Pat. No. 9,939,701, which claims the benefit of U.S. Provisional Patent Application No. 62/257,950, filed on Nov. 20, 2015, and U.S. Provisional Patent Application No. 62/258,051, filed on Nov. 20, 2015, the entire disclosures of which are incorporated herein by ...

ANTIBACTERIAL INHIBITORS

Anti-bacterial compounds have been identified having the general structures defined by Formula (I), Formula (II), and Formula (III). 3. The compound for use as defined in claim 1 , selected from the group consisting of 2-(2-nitrophenylthio) acetohydrazide claim 1 , 2-(3-nitrophenylthio)acetohydrazide claim 1 , 2-(4-nitrophenylthio)-acetohydrazide claim 1 , 2-(phenylthio)acetohydrazide claim 1 , 2-(2-fluorophenylthio)acetohydrazide claim 1 , 2-(2-chlorophenylthio) acetohydrazide claim 1 , 2-(2-hydroxyphenylthio)acetohydrazide claim 1 , 2-(2-aminophenylthio)acetohydrazide claim 1 , 2-(o-tolylthio)acetohydrazide claim 1 , 2-(2-methoxyphenylthio)-acetohydrazide claim 1 , 2 claim 1 ,3-dihydrobenzo[b]thiophene-2-carbohydrazide claim 1 , 2-(benzylthio)acetohydrazide claim 1 , 2-(pyridin-4-ylthio)acetohydrazide and 2-(naphthalen-2-ylthio)acetohydrazide.4. The compound for use as defined in claim 2 , wherein one of W claim 2 , Wand Wis OH claim 2 , NO claim 2 , NH claim 2 , halogen claim 2 , C-Calkyl claim 2 , C-Calkyl halide claim 2 , carboxyl claim 2 , acyl halide claim 2 , COR claim 2 , wherein Rand Rare independently selected from C-Calkyl claim 2 , and the other two of W claim 2 , Wand Ware each H.6Escherichia coliENTEROCOCCUS FAECALISENTEROCOCCUS FAECIUM, StreptococcusS. pneumoniae, S. viridans S. pyogenesS. pharyngitis, StaphylococcusS aureus, PseudomonasP. aeruginosaP. syringae, SalmonellaS. enterica, S. typhiS. panamaM. tuberculosis, M. bovis, M. africanum, M. microtiM. lepraeAcinetobacter baumanniiKlebsiellaKlebsiella pneumonia, K. granulomatisK. planticola.. The method of claim 5 , wherein the bacteria are selected from the group consisting of claim 5 , Enterococci such as and such as and such as such as and such as and claim 5 , Mycobacteria such as and claim 5 , Acinebacter such as and such as and7. The method of claim 5 , wherein the compound exhibits a minimal inhibitory concentration of less than 50 μg/ml.8. The method of claim 5 , wherein the compound ...

PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY

Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed. 5. A compound according to claim 1 , wherein Ris COH and Ris H or Ris COH and Ris H.6. A compound according to claim 1 , wherein Ris CORand Ris H or Ris COR claim 1 , and Ris H.7. A compound according to claim 1 , wherein Ris H claim 1 , and Ris H.8. A compound according to claim 1 , wherein Ris C-Caryl claim 1 , or alkylaryl having 1 to 3 separate or fused rings and from 6 to about 18 ring carbon atoms.9. A compound according to claim 1 , wherein Ris C-Caryl.10. A compound according to wherein Ris phenyl.11. A compound according to claim 1 , wherein FG is a fluorescent dye moiety which emits in the near infrared spectrum.12. A compound according to claim 1 , wherein FG comprises carbocyanine claim 1 , indocarbocyanine claim 1 , oxacarbocyanine claim 1 , thiacarbocyanine and merocyanine claim 1 , polymethine claim 1 , coumarine claim 1 , rhodamine claim 1 , xanthene claim 1 , fluorescein claim 1 , boron-dipyrromethane (BODIPY) claim 1 , Cy5 claim 1 , Cy5.5 claim 1 , Cy7 claim 1 , VivoTag-680 claim 1 , VivoTag-S680 claim 1 , VivoTag-S750 claim 1 , AlexaFluor660 claim 1 , AlexaFluor680 claim 1 , AlexaFluor700 claim 1 , AlexaFluor750 claim 1 , AlexaFluor790 claim 1 , Dy677 claim 1 , Dy676 claim 1 , Dy682 claim 1 , Dy752 claim 1 , Dy780 claim 1 , DyLight547 claim 1 , Dylight647 claim 1 , HiLyte Fluor 647 claim 1 , HiLyte Fluor 680 claim 1 , HiLyte Fluor 750 claim 1 , IRDye 800CW claim 1 , IRDye 800RS claim 1 , IRDye 700DX claim 1 , ADS780WS claim 1 , ADS830WS claim 1 , and ADS832WS.15. A method of imaging one or more cells claim 1 , organs or tissues by exposing the cell to or administering to an organism an effective amount of a compound according to claim 1 , where the compound includes a fluorescent dye moiety suitable for imaging.16 ...

METHOD FOR PRODUCTION OF 3-HYDROXYPROPAN-1-ONE COMPOUND, METHOD FOR PRODUCTION OF 2-PROPEN-1-ONE COMPOUND AND METHOD FOR PRODUCTION OF ISOXAZOLINE COMPOUND

There is provided a novel intermediate for producing pesticides. A method for producing the compound of Formula (3) comprises reacting an aromatic ketone compound of Formula (4) and a substituted acetophenone compound of Formula (5) as starting raw materials in an organic solvent or water in the presence or absence of an additive in the presence of a base in a suspended state. A method may comprise dehydrating the compound of Formula (3). A method for producing compound (2) in one step comprises reacting compound (4) and compound (5) to obtain compound (3). Further, a method for producing an isoxazoline compound of Formula (1) comprises reacting compound (2) and a hydroxylamine in an aliphatic or an aromatic hydrocarbon solvent which is optionally substituted by a halogen atom by adding an additive selected from a phase-transfer catalyst, a C-Calcohol and an aprotic polar solvent in the presence of a base and water. 2. The method according to claim 1 , wherein the solvent is an organic solvent and the reaction is conducted in the absence of the additive.3. The method according to claim 1 , wherein the solvent is water and the reaction is conducted in the presence of a water-soluble organic solvent as the additive.4. The method according to claim 1 , wherein the solvent is water and the reaction is conducted in the presence of a surfactant as the additive.5. The method according to claim 1 , wherein Rrepresents a halogen atom claim 1 , —C(O)OH claim 1 , —C(O)OR claim 1 , —C(O)NH claim 1 , —C(O)N(R)R claim 1 , or a substituent selected from D-21 and D-36.6. The method according to claim 5 , wherein Rrepresents a C-Calkyl optionally substituted by R—N(R)R claim 5 , —C(O)OR claim 5 , —C(O)NH claim 5 , —C(O)NHR claim 5 , or —C(R)═NOR; and{'sup': 1b', '9', '9, 'sub': 1', '6', '1', '4', '1', '4', '1', '6', '3', '6, 'Rrepresents a hydrogen atom, C-Calkyl, C-Calkoxy (C-C) alkyl, cyano (C-C) alkyl, C-Calkynyl, —C(O)Ror —C(O)OR.'}7. The method according to claim 6 , wherein ...

METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. 23-. (canceled)4. The compound of claim 1 , wherein v is 1.5. The compound of claim 1 , wherein M is a covalent bond or a C-Calkyl.612-. (canceled)13. The compound of claim 1 , wherein B is —CH(M-W)—CH—CH—. —CH—CH(M-W)—CH— claim 1 , or —(CH)—CH—CH(M-W)—.1416-. (canceled)1861-. (canceled)62. A compound of Table 3A or Table 3B claim 1 , or a pharmaceutically acceptable salt claim 1 , ester claim 1 , or prodrug thereof.63. (canceled)64. A method of treating or preventing an amyloid-related disease in a subject comprising administering to a subject in need thereof a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , in an amount effective to treat or prevent an amyloid related disease.65. The method according to claim 64 , wherein said amyloid-related disease is Alzheimer's disease claim 64 , cerebral amyloid angiopathy claim 64 , inclusion body myositis claim 64 , macular degeneration claim 64 , MCI claim 64 , or Down's syndrome.66. (canceled)67. The method according to claim 64 , wherein said amyloid-related disease is diabetes claim 64 , AA amyloidosis claim 64 , AL amyloidosis claim 64 , ATTR-related amyloidosis claim 64 , or hemodialysis related amyloidosis (βM).6870-. (canceled)71. A method for treating or preventing an amyloid-related disease in a subject in need thereof claim 17 , comprising administering to said subject a therapeutic compound of claim 17 , or a pharmaceutically acceptable salt thereof claim 17 , in an amount effective to treat or prevent an amyloid related disease.72. A method for treating or preventing an amyloid-related disease in a subject in need thereof claim 62 , comprising administering to said subject a therapeutic compound of claim 62 , or pharmaceutically acceptable salts thereof claim 62 , in an amount effective to treat or prevent an amyloid related disease.73119-. (canceled)120. The ...

AMIDE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS AND METHODS OF TREATMENT

The present disclosure relates to certain amides and heterocyclic compounds. The present disclosure also relates to uses of these compounds to inhibit Rho-associated protein kinases and treat diseases including autoimmune disorders, graft versus host disease (GVHD), inflammation, cardiovascular disorders, central nervous system disorders, and neoplastic disorders. 2. The compound of claim 1 , wherein Zis pyridine or pyrazole.4. The compound of claim 1 , wherein Zis phenyl claim 1 , pyridine claim 1 , or pyrazole claim 1 , optionally substituted with halo claim 1 , —OR′ claim 1 , —C1-C6 alkyl claim 1 , —OR′OR″ claim 1 , —O(CH)NR′R″ claim 1 , wherein the —C1-C6 alkyl is optionally substituted with one or more of —OR′ or NR′R″ claim 1 , and wherein the R′ or R″ are independently —H claim 1 , methyl or ethyl.6. The compound of claim 1 , wherein Ris H claim 1 , unsubstituted methyl claim 1 , methoxyethyl or dimethylaminoethyl.7. The compound of claim 6 , wherein Ris H.8. The compound of claim 1 , wherein R is methyl or hydroxymethyl.9. The compound of claim 8 , wherein R is hydroxymethyl with S configuration or methyl with R configuration.10. The compound of claim 1 , wherein X is a bond.12. The compound of claim 1 , wherein Ris H.13. The compound of claim 12 , wherein Ris —C3-C7 cycloalkyl or —C3-C7 cycloalkyl methyl claim 12 , and wherein the —C3-C7 cycloalkyl or —C3-C7 cycloalkyl methyl is optionally substituted with H claim 12 , halo claim 12 , —OH claim 12 , —CN claim 12 , —COOR′ claim 12 , —OR′ claim 12 , —SR′ claim 12 , —OC(O)R′ claim 12 , —NHR′ claim 12 , —NR′R″ claim 12 , —CNR′R″ claim 12 , —NHC(O)R′ claim 12 , —NHC(O)NR′R″ claim 12 , —C(O)NR′R″ claim 12 , —NS(O)R′ claim 12 , —S(O)NR′R″ claim 12 , —S(O)R′ claim 12 , guanidino claim 12 , nitro claim 12 , nitroso claim 12 , —C1-C6 alkyl claim 12 , aryl claim 12 , —C3-C7 cycloalkyl claim 12 , or 3- to 11-membered heterocycle.15. The compound of claim 12 , wherein Ris cyclopentyl or cyclohexyl.16. The compound of ...

Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b

Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R 1 , R 2 and R 4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY

Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed. 3. The composition of claim 2 , wherein the composition is adapted for administration to a subject.4. The composition of claim 3 , wherein the composition comprises a unit dosage form of compound (3).5. The composition of claim 4 , wherein the unit dosage form delivers to the subject an amount of compound (3) between about 0.01 and about 8 mg/kg.6. The composition of claim 5 , wherein the unit dosage form delivers to the subject an amount of compound (3) of about 0.01 mg/kg claim 5 , about 0.05 mg/kg claim 5 , about 0.10 mg/kg claim 5 , about 0.20 mg/kg claim 5 , about 0.3 mg/kg claim 5 , about 0.35 mg/kg claim 5 , about 0.40 mg/kg claim 5 , about 0.45 mg/kg claim 5 , about 0.50 mg/kg claim 5 , about 0.55 mg/kg claim 5 , about 0.60 mg/kg claim 5 , about 0.65 mg/kg claim 5 , about 0.70 mg/kg claim 5 , about 0.75 mg/kg claim 5 , about 0.80 mg/kg claim 5 , about 0.90 mg/kg claim 5 , about 1 mg/kg claim 5 , about 2 claim 5 , mg/kg claim 5 , about 4 mg/kg claim 5 , about 6 mg/kg claim 5 , or about 8 mg/kg.7. The composition of claim 2 , wherein the composition is in a single dose form.8. The composition of claim 2 , wherein the composition is in dry form.9. The composition of claim 2 , wherein the composition is lyophilized in a sterile container.10. The composition of claim 2 , wherein the composition is contained within a sterile container.11. The composition of claim 10 , wherein the sterile container comprises a machine detectable identifier.12. The composition of claim 2 , further comprising one or more pharmaceutically acceptable excipients in an oral dosage form.13. The composition of claim 2 , further comprising one or more pharmaceutically acceptable carriers in an injectable dosage form.14. The composition of claim 2 , further ...

Charged ion channel blockers and methods for use

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof. The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, cough, itch, and neurogenic inflammation.

CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof. The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, cough, itch, and neurogenic inflammation.

Charged ion channel blockers and methods for use

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, cough, itch, and neurogenic inflammation.

HYDROXY COMPOUND, ION CONDUCTING AGENT, AND ELECTROCONDUCTIVE RESIN COMPOSITION

Provided are a hydroxy compound and an ion conducting agent each having excellent electroconductivity. Also provided is an electroconductive resin composition suppressed in bleeding and excellent in electroconductivity through the use of the hydroxy compound. Specifically, provided are a hydroxy compound represented by the following general formula (1), and an ion conducting agent including the hydroxy compound.

PYRIDINIUM-BASED COMPOUND, EPOXY RESIN COMPOSITION COMPRISING SAME, AND APPARATUS MANUFACTURED USING SAME

The present invention relates to a pyridinium-based compound of chemical formula 1, an epoxy resin composition comprising the same, and an apparatus manufactured by using the same. 4. An epoxy resin composition , comprising:an epoxy resin, a curing agent, and a curing catalyst,{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'wherein the curing catalyst includes the pyridinium-based compound according to .'}5. The epoxy resin composition according to claim 4 , wherein the epoxy resin includes an epoxy resin having two or more epoxy groups and one or more hydroxyl groups per molecule.6. The epoxy resin composition according to claim 4 , wherein the curing agent includes a phenol resin.7. The epoxy resin composition according to claim 4 , wherein the pyridinium-based compound is present in an amount of about 0.01 wt % to about 5 wt % in the epoxy resin composition.8. The epoxy resin composition according to claim 4 , wherein the pyridinium-based compound is present in an amount of about 10 wt % to about 100 wt % in the curing catalyst.9. The epoxy resin composition according to claim 4 , further comprising an inorganic filler.10. The epoxy resin composition according to claim 9 , comprising: about 2 wt % to about 17 wt % of the epoxy resin; about 0.5 wt % to about 13 wt % of the curing agent; about 70 wt % to about 95 wt % of the inorganic filler fillers; and about 0.01 wt % to about 5 wt % of the curing catalyst.11. An epoxy resin composition for encapsulating a semiconductor device comprising the epoxy resin composition according to .12. An apparatus manufactured using the epoxy resin composition according to . The present invention relates to a pyridinium-based compound, an epoxy resin composition including the same, and an apparatus manufactured using the same.Due to advantages such as low cost and suitability for mass production, transfer molding is widely used as a method of packaging semiconductor devices, such as integrated circuits (ICs) and large scale ...

CONDUCTING REACTIONS IN LEIDENFROST-LEVITATED DROPLETS

The invention generally relates to conducting reactions in Leidenfrost-levitated droplets. 1. A method for forming a reaction product , the method comprising conducting a reaction within a Leidenfrost-levitated droplet while maintaining a substantially constant volume of the Leidenfrost-levitated droplet , thereby forming a reaction product within the Leidenfrost-levitated droplet.2. The method according to claim 1 , further comprising analyzing the reaction product.3. The method according to claim 2 , wherein analyzing is by a mass spectrometry technique.4. The method according to claim 1 , wherein maintaining the substantially constant volume comprises introducing droplets of pure solvent or the reaction mixture to the Leidenfrost-levitated droplet.5. The method according to claim 4 , wherein a rate at which the droplets of the pure solvent or reaction mixture are introduced to the Leidenfrost-levitated droplet is dependent on an evaporation rate of the Leidenfrost-levitated droplet.6. The method according to claim 1 , wherein the method further comprises conducting multiple reactions in multiple separate Leidenfrost-levitated droplets.7. The method according to claim 6 , wherein the multiple separate Leidenfrost-levitated droplets are merged with each other.8. The method according to claim 6 , wherein the multiple reactions are the same.9. The method according to claim 6 , wherein the multiple reactions are different.10. The method according to claim 1 , wherein the method is conducted without the use of surfactants.11. The method according to claim 1 , further comprising collecting the reaction product at a surface.12. A method for forming a reaction product claim 1 , the method comprising:introducing a first liquid droplet onto a heated surface that is at a temperate that is at or above a Leidenfrost point of the first liquid such that the first liquid droplet levitates on the heated surface, wherein the first liquid droplet comprises reagents for a reaction; ...

Electrochromic compounds with improved color stability in their radical states

An electrochromic device includes an electrochromic compound with reduced intermolecular interactions resulting in uncontrolled color changes, the electrochromic represented by Formula (I):

Charged ion channel blockers and methods for use

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof. The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, cough, itch, and neurogenic inflammation.

Pyridinium, quinolinium, acridinium, pyrylium, chromenylium or xanthylizum reactive desorption and/or laser ablation ionization matrices and use thereof

The present disclosure concerns use of compounds of formula I, or salts thereof, as reactive matrices for desorption and laser ablation ionization spectrometry. The disclosure further concerns compounds of formula II, or salts thereof, and use of compounds of formula II or III, or salts thereof.

Substituted enaminocarbonyl compounds

The present application relates to novel substituted enaminocarbonyl compounds of formula (I), to a method for producing said compounds and to their use for controlling animal pests, particularly arthropods and more particularly insects.

Pde4的双环杂芳基抑制剂

本发明涉及PDE4的双环杂芳基抑制剂化合物，其可以用作用于治疗或预防炎性疾病和涉及升高的细胞因子水平和促炎介质水平的其他疾病，还涉及包含所述化合物的组合物和它们作为药物用于治疗疾病的应用。

Process for preparing compound by novel sandmeyer-like reaction using nitroxide radical compound as reaction catalyst

Method for manufacturing epoxy compound, and catalyst composition for epoxylating reaction

에폭시 화합물의 제조 방법으로서, 탄소-탄소 2 중 결합을 갖는 화합물에, 텅스텐 화합물 및 몰리브덴 화합물 중 적어도 일방과, 탄소 원자를 20 이상 가지며 또한 활성 수소를 함유하는 관능기 또는 그 염으로 변환 가능한 치환기를 1 개 이상 갖는 오늄염의 존재하, 과산화수소를 작용시키는 에폭시 화합물의 제조 방법. A method for producing an epoxy compound, comprising: a compound having a carbon-carbon double bond, at least one of a tungsten compound and a molybdenum compound, and a substituent having 20 or more carbon atoms and converting into a functional group containing active hydrogen or a salt thereof; A method for producing an epoxy compound, wherein hydrogen peroxide is allowed to react in the presence of onium salts having two or more.

以高碘酸根为阴离子的Brφnsted酸性离子液体的制备方法和应用以及一种制备α,ω-二醛的方法

本发明涉及精细化工领域，具体提供了一种以高碘酸根为阴离子的 酸性离子液体的应用及其制备方法。本发明提供了一种制备α,ω-二醛的方法，该方法包括：在溶液条件下，将环烯烃和/或环氧环烷烃与氧化剂接触，得到带有白色沉淀的透明液体，分离得到白色沉淀和透明液体，其中，所述氧化剂为以高碘酸根为阴离子的 酸性离子液体。本发明首次提出以高碘酸根为阴离子的

Biaryl derivatives as agonists gpr120

FIELD: pharmacology.SUBSTANCE: invention relates to diaryl derivatives of the formula 1, or their pharmaceutically acceptable salts or isomers of formula 1, wherein A and B are independently phenyl or pyridine provided that when B is phenyl, -G-COORis substituted in the para-position of phenyl and, when B is pyridine, -G-COORis substituted in position 3 of pyridine, any of R-D and R-E may be absent, D and E are independently carbon, nitrogen, oxygen or sulfur, or represent a direct bond, and any of Rand Rmay be absent, or Ris a halogen, C-C-alkyl, optionally substituted with halogen, C-C-cycloalkyl, C-C-alkoxy, C-C-alkylamino, C-C-heterocycloalkyl or C-C-alkyl-C-C-heterocycloalkyl, C-C-cycloalkyl, optionally substituted by C-C-alkylsilanyloxy or hydroxy, C-C-alkenyl, C-C-alkynyl, C-C-heterocycloalkyl, optionally substituted by C-C-alkylamino or halogen, C-C-alkyl-C-C-heterocycloalkyl, phenyl, C-C-heteroaryl or C-C-alkyl-C-C-heteroaryl, Ris hydrogen, halogen, C-C-alkyl, optionally substituted with halogen, C-C-cycloalkyl, C-C-alkoxy, C-C-alkylamino, C-C-heterocycloalkyl or C-C-alkyl-C-C-heterocycloalkyl, C-C-cycloalkyl, optionally substituted with C-C-alkylsilaniloxy or hydroxy, C-C-alkenyl, C-C-alkynyl, C-C-heterocycloalkyl, optionally substituted with C-C-alkylamino or halogen, C-C-alkyl-C-C-heterocycloalkyl, phenyl, C-C-heteroaryl or C-C-alkyl-C-C-heteroaryl and, when D and E represent nitrogen or carbon, Rand Rmay represent two or three groups, which may be the same or different, isolated from C-C-alkyl or phenyl, G is -J-(CRC), where J is oxygen or sulfur, Rand Rindependently represent hydrogen, C-C-alkyl or C-C-cycloalkyl and Rand R, substituted in the one and the same or different carbon atoms, may be bound producing C-C-cycloalkyl, Rand Rindependently from each other may be absent depending on m and n value or independently represent hydrogen, halogen or C-C-alkyl, or C-C-alkoxy, Ris hydrogen or C-C-alkyl, m and n independently represent an integral number ...

Биарильные производные в качестве агонистов gpr120

А 2016102313 ко РОССИЙСКАЯ ФЕДЕРАЦИЯ 19 РЦ 1? заб ча 9343 Д (51) МПК С07Р 213/30 (2006.01) АФК 31/4412 (2006.01) Аб1Р 300 (2006.01) АбР 2900 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2016102313, 26.06.2014 (71) Заявитель(и): Эл Джи ЛАЙФ САЙЕНСИЗ ЛТД. (КВ) Приоритет(ы): (30) Конвенционный приоритет: (72) Автор(ы): 27.06.2013 КВ 10-2013-0074927 КИМ Янг Кван (КВ), ПАРК Санг Юн (КВ) 4 : 01.08.2017 Бюл. № 22 (43) Дата публикации заявки юл. № ДЗОО Хиун Воо (КВ), (85) Дата начала рассмотрения заявки РСТ на ЧОИ Еун Сил (КВ) национальной фазе: 27.01.2016 (86) Заявка РСТ: КК 2014/005688 (26.06.2014) (87) Публикация заявки РСТ: УГО 2014/209034 (31.12.2014) Адрес для переписки: 129090, Москва, ул. Б.Спасская, 25, строение 3, ООО "Юридическая фирма Городисский и Партнеры" (54) БИАРИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АГОНИСТОВ СРК120 (57) Формула изобретения 1. Диарильные производные формулы 1 или их фармацевтически приемлемые соли или изомеры: [Формула 1] В {а им р . < { х с р К. ое А тх > &--соо8, , в которой А и В независимо представляют собой фенил или пиридин, любой из К|-РиК)>-Е не может существовать, В и Е независимо представляют собой углерод, азот, кислорода или серу, или представляют собой непосредственную связь, и любой из К | иК)> может не существовать, или К | и К› независимо представляют собой водород, галоген, необязательно замещенный С-Св-алкил, Сз-С10-циклоалкил, С>-Св -алкенил, С>-Св-алкинил, Сз-С10-гетероциклоалкил, С1-Св-алкил-Сз-С1о-циклоалкил, С1-Св-алкил-Сз-Сло-гетероциклоалкил, арил, С1-Св-алкиларил, гетероарил или С1-Св -алкил-С5-Св-гетероалкил, и когда Ри Е представляют собой азот или углерод, К] и Стр.: 1 па 090 сС У А 2016102313 ко В могут представлять собой два или три необязательно замещенных С!-Сб-алкила, Сз -С10-Циклоалкила, С>-Св-алкенила, С>-Св-алкинила, С1-Св-алкил-Сз-С10-циклоалкила, арила или С!-Сб-алкиларила, которые могут быть одинаковыми или различными, С представляет собой -/-( ...

Ketone or oxime compound and herbicide

FIELD: chemistry. SUBSTANCE: present invention relates to an oxime compound or salt thereof of formula (1), which can be used as a herbicide: , where B is a ring from any one of B-1-a or B-2-a ; Q is =NOR 7 ; and R 6 , R 8a , R 8b , R 9a , R 9b , R 10 -R 12 , A, Z a , Z b , Z c , m, n have values given in the claim. EFFECT: disclosed are a ketone or oxime compound and an herbicide. 3 cl, 26 tbl, 23 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (51) МПК C07C 251/40 (2006.01) C07D 213/04 (2006.01) C07D 231/12 (2006.01) C07D 233/54 (2006.01) C07D 249/08 (2006.01) C07D 317/12 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА C07D 333/04 (2006.01) ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ C07D 239/24 (2006.01) C07F 7/08 (2006.01) A01N 33/16 (2006.01) (12) (13) 2 716 016 C2 A01N 43/28 (2006.01) A01N 43/56 (2006.01) A01N 43/40 (2006.01) A01N 43/54 (2006.01) A01N 43/653 (2006.01) A01N 43/50 (2006.01) A01N 43/10 (2006.01) A01N 55/10 (2006.01) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК (21)(22) Заявка: 2017124978, 18.12.2015 18.12.2015 Дата регистрации: 05.03.2020 18.12.2014 JP 2014-255973; 18.02.2015 JP 2015-029704; 15.04.2015 JP 2015-083620; 08.07.2015 JP 2015-136991 (73) Патентообладатель(и): НИССАН КЕМИКАЛ ИНДАСТРИЗ, ЛТД. (JP) (43) Дата публикации заявки: 21.01.2019 Бюл. № 3 R U 2 7 1 6 0 1 6 (45) Опубликовано: 05.03.2020 Бюл. № 7 (56) Список документов, цитированных в отчете о поиске: WO 2010102848 A1, 16.09.2010. WO 2010089210 A1, 12.08.2010. WO 2010000773 A1, 07.01.2010. RU 2280643 C2, 27.07.2006. (85) Дата начала рассмотрения заявки PCT на национальной фазе: 18.07.2017 (86) Заявка PCT: JP 2015/085569 (18.12.2015) (87) Публикация заявки PCT: WO 2016/098899 (23.06.2016) Адрес для переписки: 129090, Москва, ул. Большая Спасская, д. 25, строение 3, ООО "Юридическая фирма Городисский и Партнеры" (54) СОЕДИНЕНИЕ КЕТОНА ИЛИ ОКСИМА И ГЕРБИЦИД (57) Реферат: Настоящее изобретение относится к гербицида: соединению оксима или его соли формулы (1), которое может быть использовано в качестве Стр.: 1 C 2 C 2 Приоритет(ы): ...

Pyridinium based compound, epoxy resin composition comprising the same and apparatus prepared from using the same

본 발명은 화학식 1의 피리디늄계 화합물, 이를 포함하는 에폭시수지 조성물 및 이를 사용하여 제조된 장치에 관한 것이다. The present invention relates to a pyridinium compound of formula (I), an epoxy resin composition containing the same, and an apparatus manufactured using the same.

Platinum complex dioxygen sensors

The luminescent platinum 1,2-enedithiolates are dual emitters with a short-lived 1 ILCT* singlet and long-lived oxygen-sensing 3 ILCT* triplet (ILCT; intraligand charge transfer transition) emissive excited states. Since only the triplet is quenched by molecular oxygen, the singlet serves as an internal standard for dioxygen measurements. This allows the concentration of dioxygen to be determined from the ratio of the singlet/triplet emissions. The novel dual emitters are readily polymer encapsulated to allow measurement of dioxygen in a range of settings. These polymer encapsulated dual emitters will serve as a drop-in step-out replacement sensor for currently available dioxygen measuring devices.

Соединение кетона или оксима и гербицид

РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2017 124 978 A (51) МПК C07C 49/747 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2017124978, 18.12.2015 (71) Заявитель(и): НИССАН КЕМИКАЛ ИНДАСТРИЗ, ЛТД. (JP) Приоритет(ы): (30) Конвенционный приоритет: (43) Дата публикации заявки: 21.01.2019 Бюл. № 03 (86) Заявка PCT: JP 2015/085569 (18.12.2015) (87) Публикация заявки PCT: Адрес для переписки: 129090, Москва, ул. Большая Спасская, д. 25, строение 3, ООО "Юридическая фирма Городисский и Партнеры" (54) СОЕДИНЕНИЕ КЕТОНА ИЛИ ОКСИМА И ГЕРБИЦИД R U (57) Формула изобретения 1. Соединение кетона или оксима или его соль формулы (1): Стр.: 1 A 2 0 1 7 1 2 4 9 7 8 A WO 2016/098899 (23.06.2016) 2 0 1 7 1 2 4 9 7 8 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 18.07.2017 (72) Автор(ы): НУМАТА Акира (JP), ИВАВАКИ Юдзи (JP), ФУРУКАВА Юки (JP), ЙОСИНО Юри (JP), МИЯКАДО Юуки (JP), ФУРУХАСИ Такамаса (JP), МИЯДЗАКИ Такао (JP) R U 18.12.2014 JP 2014-255973; 18.02.2015 JP 2015-029704; 15.04.2015 JP 2015-083620; 08.07.2015 JP 2015-136991 , замещенный с помощью R5, C2-6 алкенил, C3-8 циклоалкенил, (C3-8) циклоалкенил, произвольно замещенный с помощью R5, (C2-6) алкенил, произвольно замещенный с помощью R5, C2-6 алкинил, (C2-6) алкинил, произвольно замещенный с помощью R5, -S(O)r2R1, -C(O)OR1, -C(S)OR1, -C(O)SR1, -C(S)SR1, -C(O)R2, -C(S)R2, -C(O)N(R4)R3, -C(S) N(R4)R3, -S(O)2N(R4)R3, -P(O)(OR1)2 или -P(S)(OR1)2; R1 представляет собой C1-8 алкил, (C1-6) алкил, произвольно замещенный с помощью R5, C3-8 циклоалкил, (C3-8) циклоалкил, произвольно замещенный с помощью R5, C2-6 A R U алкенил, (C2-6) алкенил, произвольно замещенный с помощью R5, C3-8 циклоалкенил, (C3-8) циклоалкенил, произвольно замещенный с помощью R5, C2-6 алкинил, (C2-6) алкинил, произвольно замещенный с помощью R5, фенил или фенил, замещенный с помощью (Z2)q2; R2 представляет собой атом водорода, C1-8 алкил, (C1-6) алкил, произвольно Стр.: 2 A 2 0 1 7 1 2 ...

Novel compound, light-emitting device including the compound and electronic device

본 발명은 하기 화학식 1로 나타내는 화합물을 포함한다. [화학식 1] 화학식 1에서, X 1 , X 2 , Y 1 , Y 2 , Z 1 및 Z 2 는 각각 독립적으로 C-R a 또는 N을 나타내며, p 및 q는 각각 독립적으로 0 또는 1을 나타내되, p+q=1 또는 2이고, R a , R 3 , R 4 , R 5 및 R 6 은 각각 독립적으로 수소, 페닐기, 피리디닐기 또는 하기 화학식 2로 나타내고, [화학식 2] R 3 및 R 4 중 어느 하나 이상이 화학식 2로 나타내는 치환기인 경우에는, R 5 및 R 6 중 어느 하나 이상은 화학식 2로 나타내는 치환기이고, R 7 은 수소 또는 탄소수 1 내지 30을 갖는 알킬기를 나타낸다.

Method for producing epoxy compound and catalyst composition for epoxidation reaction

A method of producing an epoxy compound, which comprises reacting hydrogen peroxide with a compound having a carbon-carbon double bond, in the presence of at least one of a tungsten compound and a molybdenum compound; and an onium salt comprising 20 or more carbon atoms and one or more of substituents convertible to a functional group containing an active hydrogen or a salt thereof.

Method of producing epoxy compound and catalyst composition for epoxidation reaction

A method of producing an epoxy compound, which comprises reacting hydrogen peroxide with a compound having a carbon-carbon double bond, in the presence of at least one of a tungsten compound and a molybdenum compound; and an onium salt comprising 20 or more carbon atoms and one or more of substituents convertible to a functional group containing an active hydrogen or a salt thereof.

Aldehyde group pyridine derivative showing FGFR4 inhibitory activity, its production method and application

Substituted enaminocarbonyl compounds

Substituted enaminocarbonyl compounds

Substituted enaminocarbonyl compounds

Substituted enaminocarbonyl compounds

The present invention relates to novel substituted enaminocarbonyl compounds, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects.

Substituted enaminocarbonyl compounds

본 발명은 신규 치환된 엔아미노카보닐 화합물, 그의 제조방법 및 동물 해충, 특히 절지동물, 그 중에서도 곤충을 구제하기 위한 그의 용도에 관한 것이다. The present invention relates to novel substituted enaminocarbonyl compounds, processes for their preparation and their use for rescuing insects, especially arthropods, especially insects.

Substituted enaminocarbonyl compounds.

La presente invención se refiere a nuevos compuestos de enaminocarbonilo de fórmula (I), a procedimientos para su preparación y a su uso para combatir plagas animales, ante todo artrópodos, particularmente insectos.

Substituted enaminocarbonyl compounds

The present application relates to novel substituted enaminocarbonyl compounds of formula (I), to a method for producing said compounds and to their use for controlling animal pests, particularly arthropods and more particularly insects.

substituted enaminocarbonyl compounds, composition, uses, and pest control process

<b>compostos enaminocarbonila substituidos<d> a presente invenção refere-se a novos compostos enaminocar-bonila substituidos da fórmula (1), a processos para sua preparação e ao seu uso para o combate de pragas animais, sobretudo de artrópodes, particularmente insetos. Substituted Enaminocarbonyl Compounds The present invention relates to novel substituted enaminocarbonyl compounds of formula (1), processes for their preparation and their use for the control of animal pests, particularly arthropods, particularly insects. .

Substituted enaminocarbonyl compounds

Compuestos de fórmula (I)**Fórmula** en la que A representa pirid-2-ilo o pirid-4-ilo o pirid-3-ilo que dado el caso está sustituido en posición 6 con flúor, cloro, bromo, metilo, trifluorometilo o trifluorometoxi, o representa piridazin-3-ilo que dado el caso está sustituido en posición 6 con cloro o metilo, o representa pirazin-3-ilo o 2-cloropirazin-5-ilo o 1,3-tiazol-5-ilo que dado el caso está sustituido en posición 2 con cloro o metilo, B representa oxígeno, azufre o metileno, R1 representa haloalquilo, haloalquenilo, halocicloalquilo o halocicloalquilalquilo, R2 representa hidrógeno o halógeno, y R3 representa hidrógeno o alquilo. Compounds of formula (I) ** Formula ** in which A represents pyrid-2-yl or pyrid-4-yl or pyrid-3-yl which optionally is substituted in position 6 with fluorine, chlorine, bromine, methyl , trifluoromethyl or trifluoromethoxy, or represents pyridazin-3-yl which is optionally substituted in position 6 with chlorine or methyl, or represents pyrazin-3-yl or 2-chloropyrazin-5-yl or 1,3-thiazol-5- yl which is optionally substituted in position 2 with chlorine or methyl, B represents oxygen, sulfur or methylene, R1 represents haloalkyl, haloalkenyl, halocycloalkyl or halocycloalkylalkyl, R2 represents hydrogen or halogen, and R3 represents hydrogen or alkyl.

Substituted enaminocarbonyl compounds

본 발명은 신규 치환된 엔아미노카보닐 화합물, 그의 제조방법 및 동물 해충, 특히 절지동물, 그 중에서도 곤충을 구제하기 위한 그의 용도에 관한 것이다. The present invention relates to novel substituted enaminocarbonyl compounds, processes for their preparation and their use for rescuing insects, especially arthropods, especially insects.

SUBSTITUTED ENAMINOCARBONYL COMPOUNDS

Substituted enaminocarbonyl compounds.

La presente invención se refiere a nuevos compuestos de enaminocarbonilo de fórmula (I), a procedimientos para su preparación y a su uso para combatir plagas animales, ante todo artrópodos, particularmente insectos.

Substituted enaminocarbonyl compounds

本发明涉及新的式(I)的被取代的烯氨羰基化合物，涉及制备所述化合物的方法及其用于防治动物害虫、特别是节肢动物、尤其是昆虫的用途。

Substituted enaminocarbonyl compounds

The present invention relates to novel substituted enaminocarbonyl compounds, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects.

Substituted enaminocarbonyl compounds

The present invention relates to novel substituted enaminocarbonyl compounds, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects.

flupyradifurone

Substituted enaminocarbonyl compounds

New cyclic enamine ketone derivatives useful for controlling pests, especially insects

Cyclic enamine ketone derivatives (I) are new. Cyclic enamine ketone derivatives of formula (I) are new. A : 2-pyridyl, 4-pyridyl, 6-X 1>-3-pyridyl, 6-X 2>-3-pyridazinyl, 3-pyrazinyl or 2-X 2>-5-thiazolyl; X 1> : H, F, Cl, Br, Me, CF 3or OCF 3; X 2> : H, Cl or Me; B' : O, S or CH 2; R 1> : haloalkyl, haloalkenyl, halocycloalkyl or halocycloalkylalkyl; R 2> : H or halo; R 3> : H or alkyl. [Image] ACTIVITY : Insecticide. In a test against Myzus persicae, 4-(N-(6-chloro-3-pyridylmethyl)-N-(2-fluoroethyl)amino)-2(5H)-furanone gave 100% kill after 6 days at a concentration of 0.8 ppm. MECHANISM OF ACTION : None given.

Substituted enaminocarbonyl compounds

本发明涉及新的式(I)的被取代的烯氨羰基化合物，涉及制备所述化合物的方法及其用于防治动物害虫、特别是节肢动物、尤其是昆虫的用途。

SUBSTITUTED ENAMINOCARBONYL COMPOUNDS

Reivindicacion 1: Compuestos de formula (1) en la que A representa pirid-2-ilo o pirid-4-ilo o pirid-3-ilo que dado el caso está sustituido en posicion 6 con fluor, cloro, bromo, metilo, trifluorometilo o trifluorometoxi, o representa piridazin-3- ilo que dado el caso está sustituido en posicion 6 con cloro o metilo, o representa pirazin-3-ilo o 2-cloropirazin-5-ilo o 1,3-tiazol-5-ilo que dado el caso está sustituido en posicion 2 con cloro o metilo, B representa oxígeno, azufre o metileno, R1 representa halogenoalquilo, halogenoalquenilo, halogenocicloalquilo o halogenocicloalquilalquilo, R2 representa hidrogeno o halogeno, y R3 representa hidrogeno o alquilo. Claim 1: Compounds of formula (1) wherein A represents pyrid-2-yl or pyrid-4-yl or pyrid-3-yl which, if necessary, is substituted in position 6 with fluorine, chlorine, bromine, methyl, trifluoromethyl or trifluoromethoxy, or represents pyridazin-3- yl which, if necessary, is substituted in position 6 with chlorine or methyl, or represents pyrazin-3-yl or 2-chloropyrazine-5-yl or 1,3-thiazol-5-yl which if necessary, it is substituted in position 2 with chlorine or methyl, B represents oxygen, sulfur or methylene, R1 represents halogenoalkyl, halogenoalkenyl, halogenocycloalkyl or halogenocycloalkylalkyl, R2 represents hydrogen or halogen, and R3 represents hydrogen or alkyl.

Substituted N-carbonyl compounds

Η παρούσα αίτηση αφορά νέες υποκατεστημένες εναμινοκαρβονυλ ενώσεις του τύπου (I), μια μέθοδο για την παραγωγή των εν λόγω ενώσεων και τη χρήση αυτών για τον έλεγχο ζωικών ζιζανίων, ιδιαιτέρως αρθροπόδων και πιο συγκεκριμένα εντόμων. The present application relates to novel substituted enaminocarbonyl compounds of formula (I), a method for the production of said compounds and their use in the control of animal weeds, particularly arthropods and more specifically insects.

Use of substituted enaminocarbonyl compounds to combat animal pests

Uso de un compuesto de fórmula (I)**Fórmula** en la que A representa pirid-3-ilo que está sustituido en posición 6 con flúor, cloro, bromo, metilo o trifluorometilo, o representa 2-cloropirazin-5-ilo o 2-cloro-1,3-tiazol-5-ilo, B representa oxígeno, azufre o metilfeno, R1 representa haloalquilo C1-3, haloalquenilo C2-3, halociclopropilo , R2 representa hidrógeno o halógeno, y R3 representa hidrógeno o metilo, para combatir insectos, arácnidos y nematodos que se presentan en silvicultura, en protección de productos almacenados y materiales. Use of a compound of formula (I) ** Formula ** in which A represents pyrid-3-yl which is substituted in position 6 with fluorine, chlorine, bromine, methyl or trifluoromethyl, or represents 2-chloropyrazine-5-yl or 2-chloro-1,3-thiazol-5-yl, B represents oxygen, sulfur or methylphene, R1 represents C1-3 haloalkyl, C2-3 haloalkenyl, halocyclopropyl, R2 represents hydrogen or halogen, and R3 represents hydrogen or methyl, to combat insects, arachnids and nematodes that occur in forestry, in protection of stored products and materials.

Substituted enaminocarbonyl compounds

Substituted enaminocarbonyl compounds

Substituted enaminocarbonyl compounds

Substituted enaminocarbonyl compounds

Use of substituted enaminocarbonyl compounds for combating animal pests

Use of substituted enaminocarbonyl compounds for combating animal pests

Substituted enaminocarbonyl compounds

Substituted enaminocarbonyl compounds

Substituted enaminocarbonyl compounds

Substituted enaminocarbonyl compounds

The present application relates to novel substituted enaminocarbonyl compounds of formula (I), to a method for producing said compounds and to their use for controlling animal pests, particularly arthropods and more particularly insects.

substituted enaminocarbonyl compounds

<B>COMPOSTOS ENAMINOCARBONILA SUBSTITUIDOS<D> A presente invenção refere-se a novos compostos enaminocar-bonila substituidos da fórmula (1), a processos para sua preparação e ao seu uso para o combate de pragas animais, sobretudo de artrópodes, particularmente insetos. Substituted ENAMINOCARBONYL COMPOUNDS The present invention relates to novel substituted enaminocarbonyl compounds of formula (1), processes for their preparation and their use for combating animal pests, particularly arthropods, particularly insects. .

Use of substituted enaminocarbonyl compounds for combating animal pests

Cyclic enamine ketone derivatives (I) are new. Cyclic enamine ketone derivatives of formula (I) are new. A : 2-pyridyl, 4-pyridyl, 6-X 1>-3-pyridyl, 6-X 2>-3-pyridazinyl, 3-pyrazinyl or 2-X 2>-5-thiazolyl; X 1> : H, F, Cl, Br, Me, CF 3or OCF 3; X 2> : H, Cl or Me; B' : O, S or CH 2; R 1> : haloalkyl, haloalkenyl, halocycloalkyl or halocycloalkylalkyl; R 2> : H or halo; R 3> : H or alkyl. [Image] ACTIVITY : Insecticide. In a test against Myzus persicae, 4-(N-(6-chloro-3-pyridylmethyl)-N-(2-fluoroethyl)amino)-2(5H)-furanone gave 100% kill after 6 days at a concentration of 0.8 ppm. MECHANISM OF ACTION : None given.

substituted enaminocarbonyl compounds, composition, uses, and pest control process

<b>compostos enaminocarbonila substituidos<d> a presente invenção refere-se a novos compostos enaminocar-bonila substituidos da fórmula (1), a processos para sua preparação e ao seu uso para o combate de pragas animais, sobretudo de artrópodes, particularmente insetos. Substituted Enaminocarbonyl Compounds The present invention relates to novel substituted enaminocarbonyl compounds of formula (1), processes for their preparation and their use for the control of animal pests, particularly arthropods, particularly insects. .

Substituted enaminocarbonyl compounds

Substituted enaminocarbonyl compounds

本发明涉及新的式(I)的被取代的烯氨羰基化合物，涉及制备所述化合物的方法及其用于防治动物害虫、特别是节肢动物、尤其是昆虫的用途。